Validation of the utility of Agile scores to identify advanced fibrosis and cirrhosis in Japanese patients with nonalcoholic fatty liver disease

被引:5
|
作者
Oeda, Satoshi [1 ,2 ]
Seko, Yuya [3 ]
Hayashi, Hideki [4 ]
Arai, Taeang [5 ]
Iwaki, Michihiro [6 ]
Yoneda, Masato [6 ]
Shima, Toshihide [7 ]
Notsumata, Kazuo [8 ]
Ikegami, Tadashi [9 ]
Fujii, Hideki [10 ]
Toyoda, Hidenori [11 ]
Miura, Kouichi [12 ]
Morishita, Asahiro [13 ]
Kawata, Kazuhito [14 ]
Tomita, Kengo [15 ]
Kawanaka, Miwa [16 ]
Isoda, Hiroshi
Yamaguchi, Kanji
Fukushima, Hideaki [17 ]
Kamada, Yoshihiro [18 ]
Sumida, Yoshio [19 ]
Aishima, Shinichi [20 ]
Itoh, Yoshito [3 ]
Okanoue, Takeshi [7 ]
Nakajima, Atsushi [6 ]
Takahashi, Hirokazu [1 ]
Japan Study Grp Nonalcohol Fatty Liver Dis JSG NAFLD
机构
[1] Saga Univ Hosp, Liver Ctr, Saga, Japan
[2] Saga Univ Hosp, Dept Lab Med, Saga, Japan
[3] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Mol Gastroenterol & Hepatol, Kyoto, Japan
[4] Gifu Municipal Hosp, Dept Gastroenterol & Hepatol, Gifu, Japan
[5] Nippon Med Sch, Dept Internal Med, Div Gastroenterol & Hepatol, Tokyo, Japan
[6] Yokohama City Univ, Dept Gastroenterol & Hepatol, Grad Sch Med, Yokohama, Japan
[7] Saiseikai Suita Hosp, Dept Gastroenterol & Hepatol, Suita, Japan
[8] Fukui ken Saiseikai Hosp, Dept Gen Internal Med, Fukui, Japan
[9] Tokyo Med Univ, Dept Gastroenterol & Hepatol, Ibaraki Med Ctr, Ibaraki, Japan
[10] Osaka Metropolitan Univ, Dept Hepatol, 5-1-1 Nabeshima, Osaka 8498501, Japan
[11] Ogaki Municipal Hosp, Dept Gastroenterol & Hepatol, Ogaki, Japan
[12] Jichi Med Univ, Dept Med, Div Gastroenterol, Tochigi, Japan
[13] Kagawa Univ, Fac Med, Dept Gastroenterol & Neurol, Takamatsu, Japan
[14] Hamamatsu Univ, Dept Internal Med 2, Hepatol Div, Sch Med, Hamamatsu, Japan
[15] Natl Def Med Coll, Dept Internal Med, Saitama, Japan
[16] Kawasaki Med Sch, Gen Med Ctr, Gen Internal Med 2, Okayama, Japan
[17] Siemens Healthcare Diagnost KK, Diagnost Business Area, Tokyo, Japan
[18] Osaka Univ, Dept Adv Metab Hepatol, Grad Sch Med, Suita, Japan
[19] Aichi Med Univ, Dept Internal Med, Div Hepatol & Pancreatol, Nagakute, Aichi, Japan
[20] Saga Univ, Fac Med, Dept Pathol & Microbiol, Saga, Japan
关键词
elastography; fibrosis; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; ultrasound; STIFFNESS; SYSTEM; BIOPSY;
D O I
10.1111/hepr.13890
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AimAgile 3+ and Agile 4 scores, based on liver stiffness measurement (LSM) by transient elastography and clinical parameters, were recently reported to be effective in identifying advanced fibrosis and cirrhosis in nonalcoholic fatty liver disease (NAFLD). This study aimed to validate the utility of these scores in Japanese patients with NAFLD. MethodsSix hundred forty-one patients with biopsy-proven NAFLD were analyzed. The severity of liver fibrosis was pathologically evaluated by one expert pathologist. The LSM, age, sex, diabetes status, platelet count, and aspartate aminotransferase and alanine aminotransferase levels were used to calculate Agile 3+ scores, and the parameters above excluding age were used for Agile 4 scores. The diagnostic performance of the two scores was evaluated using receiver operating characteristic (ROC) curve analysis. Sensitivity, specificity, and predictive values of the original low cut-off (for rule-out) value and high cut-off (for rule-in) value were tested. ResultsFor diagnosis of fibrosis stage >= 3, the area under the ROC (AUROC) was 0.886, and the sensitivity of the low cut-off value and the specificity of the high cut-off value were 95.3% and 73.4%, respectively. For diagnosis of fibrosis stage 4, AUROC, the sensitivity of the low cut-off value, and the specificity of the high cut-off value were 0.930, 100%, and 86.5%, respectively. Both scores had higher diagnostic performance than the FIB-4 index and the enhanced liver fibrosis score. ConclusionsAgile 3+ and Agile 4 are reliable noninvasive tests to identify advanced fibrosis and cirrhosis in Japanese NAFLD patients with adequate diagnostic performance.
引用
收藏
页码:489 / 496
页数:8
相关论文
共 50 条
  • [41] Patients with uncertain advanced fibrosis and cirrhosis diagnosis by Agile3+and Agile4 scores cannot be excluded in validation studies
    Ferreira, Luis Fernando
    Manica, Muriel
    Nogueira, Cristiane Villela
    Tovo, Cristiane Valle
    [J]. HEPATOLOGY RESEARCH, 2024, 54 (05) : 495 - 496
  • [42] Exploring factors related to clinically advanced fibrosis in patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis
    Yu, Anthony
    Ritenour, Alexandra
    Vincent, Jennifer
    Park, Chanhyun
    Rascati, Karen
    Godley, Paul
    [J]. POSTGRADUATE MEDICINE, 2024, 136 (01) : 14 - 21
  • [43] Performance of the Enhanced Liver Fibrosis Test to Estimate Advanced Fibrosis Among Patients With Nonalcoholic Fatty Liver Disease
    Younossi, Zobair M.
    Felix, Sean
    Jeffers, Thomas
    Younossi, Elena
    Nader, Fatema
    Pham, Huong
    Afendy, Arian
    Cable, Rebecca
    Racila, Andrei
    Younoszai, Zahra
    Lam, Brian P.
    Golabi, Pegah
    Henry, Linda
    Stepanova, Maria
    [J]. JAMA NETWORK OPEN, 2021, 4 (09)
  • [44] IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE
    Bian, Hua
    Zhu, Xiaopeng
    Xia, Mingfeng
    Yan, Hongmei
    Chang, Xinxia
    Hu, Xiqi
    Pan, Baishen
    Guo, Wei
    Li, Xiaoying
    Gao, Xin
    [J]. ENDOCRINE PRACTICE, 2020, 26 (04) : 444 - 453
  • [45] The diagnostic utility of fibrosis-4 or nonalcoholic fatty liver disease fibrosis score combined with liver stiffness measurement by fibroscan in assessment of advanced liver fibrosis: a biopsy-proven nonalcoholic fatty liver disease study
    Jafarov, Fuad
    Kaya, Eda
    Bakir, Alev
    Eren, Fatih
    Yilmaz, Yusuf
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2020, 32 (05) : 642 - 649
  • [46] Evaluation of fibrosis in patients with nonalcoholic fatty liver disease
    Montano-Loza, Aldo J.
    [J]. REVISTA DE GASTROENTEROLOGIA DE MEXICO, 2022, 87 (01): : 1 - 3
  • [48] UTILITY OF METABOLOMIC BIOMARKERS TO IDENTIFY NONALCOHOLIC FATTY LIVER DISEASE IN LIVER TRANSPLANT RECIPIENTS
    Mowry, Christopher J.
    Rinella, Mary E.
    Iruarrizaga-Lejarreta, Marta
    Alonso, Cristina
    Ortiz, Pablo
    Levitsky, Josh
    [J]. GASTROENTEROLOGY, 2020, 158 (06) : S1410 - S1410
  • [49] Utility of Metabolomic Biomarkers to Identify Nonalcoholic Fatty Liver Disease in Liver Transplant Recipients
    Mowry, Christopher J.
    Alonso, Cristina
    Iruarrizaga-Lejarreta, Marta
    Ortiz, Pablo
    Levitsky, Josh
    Rinella, Mary
    [J]. TRANSPLANTATION DIRECT, 2021, 7 (12): : E784
  • [50] INCIDENCE AND CLINICAL CHARACTERISTICS OF HEPATOCELLULAR CARCINOMA ASSOCIATED WITH NONALCOHOLIC FATTY LIVER DISEASE WITHOUT CIRRHOSIS OR ADVANCED LIVER FIBROSIS
    Behari, Jaideep
    Wang, Renwei
    Luu, Hung N.
    Paragomi, Pedram
    Yu, Yi-Chuan
    Molinari, Michele
    Chopra, Kapil B.
    Malik, Shahid M.
    Geller, David A.
    Yuan, Jian-Min
    [J]. HEPATOLOGY, 2021, 74 : 90A - 90A